Eosinophilic Esophagitis - Healthcare Professionals

A Randomized double-blindplacebo-controlled trial of oralviscous Budesonide for EoE• 24 patients: 15 treated with OVB and 9placebo treated controls for 3 months• Primary endpoint: histologic with eosinophilcount < 6/hpf.• Results: 87% in treatment and 0% in placebogroup demonstrated histologic remission.• Taller patients were more likely to be partialresponders